Yisheng Pharma Halts Production of Key Drugs After Regulatory Action
Yisheng Pharmaceutical announced on July 1st that it received a notice from the Jilin Provincial Drug Administration regarding risk control measures. The notice mandates the suspension of production and sales for two of the company's products: Shengmai Injection and Bujin Tablets. This action was prompted by the discovery of serious defects in the Bujin Tablets. Consequently, the production lines for both Shengmai Injection and Bujin Tablets are now halted. In 2025, Shengmai Injection accounted for 7.65% of Yisheng Pharma's total revenue, while Bujin Tablets contributed a mere 0.01%. The company has initiated a Level 3 recall for Bujin Tablets. As of the announcement, Yisheng Pharma has not received any reports of adverse safety events related to these products. The company stated it is actively working on rectifications to address the issues raised by the regulatory body.
The regulatory action against Yisheng Pharma highlights the critical role of product quality and compliance in the pharmaceutical industry. The suspension of production for Shengmai Injection and Bujin Tablets, impacting a significant portion of the company's revenue, underscores the financial repercussions of manufacturing defects. While the company has initiated a recall and pledged to rectify the situation, the incident raises questions about the robustness of its quality control systems. Moving forward, Yisheng Pharma will need to demonstrate a sustained commitment to regulatory standards to regain market confidence and mitigate future risks. The event also serves as a reminder for the broader industry to prioritize stringent quality assurance protocols to prevent similar disruptions and safeguard public health.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.